Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Declines By 29.2%

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large drop in short interest in March. As of March 31st, there was short interest totaling 705,229 shares, a drop of 29.2% from the March 15th total of 995,395 shares. Approximately 2.3% of the company’s stock are sold short. Based on an average daily volume of 1,409,416 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Liminatus Pharma presently has an average rating of “Sell”.

Liminatus Pharma Stock Performance

NASDAQ LIMN opened at $0.18 on Tuesday. The company has a market capitalization of $8.08 million and a PE ratio of -1.20. The business’s fifty day moving average is $0.39 and its 200 day moving average is $0.80. Liminatus Pharma has a fifty-two week low of $0.16 and a fifty-two week high of $33.66.

Liminatus Pharma (NASDAQ:LIMN) last released its earnings results on Tuesday, March 31st. The company reported ($0.34) earnings per share for the quarter.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.